CLINICAL FEATURES, RISK FACTORS, AND THERAPEUTIC APPROACHES IN AGE-RELATED MACULAR DEGENERATION (AMD)

Yusupov Mirza Murodovich
Senior Lecturer of the Department of Physiology,
Samarkand State Technical University

Annotation: Age-related macular degeneration (AMD) is one of the leading causes of irreversible vision loss in individuals over 50 years of age in developed countries. It primarily affects the macula, the central region of the retina responsible for sharp, detailed vision. AMD is typically categorized into two forms: dry (atrophic) and wet (neovascular or exudative). The dry form is more common and progresses slowly, while the wet form is less prevalent but more severe and can lead to rapid vision loss. This article explores the clinical features, risk factors, diagnostic tools, and treatment strategies for AMD. Utilizing a structured methodological approach, it evaluates patient data, imaging results, and treatment outcomes across various stages of the disease. The findings emphasize the role of early diagnosis and the application of anti-VEGF therapies and lifestyle interventions in managing AMD progression and preserving visual function.

Key words: Age-related macular degeneration (AMD),Dry AMD,Wet AMD, Geographic atrophy,Choroidal neovascularization,Optical coherence tomography (OCT),Anti-VEGF therapy,Visual acuity,Retinal imaging,Smoking and AMD,AREDS2 supplementation,Risk factors,Retinal pigment epithelium.

Introduction: Age-related macular degeneration (AMD) is a chronic, progressive eye disease that primarily affects the macula, the central portion of the retina responsible for fine visual tasks such as reading, driving, and recognizing faces. As the global population ages, AMD has become an increasingly significant public health concern, particularly in industrialized nations. Current estimates suggest that over 190 million people worldwide are affected by some form of AMD, with numbers expected to rise substantially in the coming decades due to demographic shifts. AMD is broadly classified into two major types: dry (non-neovascular) AMD and wet (neovascular) AMD. The dry form accounts for approximately 85–90% of all AMD cases and is characterized by the presence of drusen—yellowish deposits under the retina—and gradual thinning of the macular retinal pigment epithelium (RPE). Over time, these changes can lead to geographic atrophy and central vision loss. Wet AMD, on the other hand, involves abnormal blood vessel growth (choroidal neovascularization) beneath the retina, resulting in fluid leakage, hemorrhage, and scarring. Although less common, wet AMD is responsible for the majority of severe vision loss associated with the disease. The pathogenesis of AMD is multifactorial,

involving genetic predisposition, oxidative stress, chronic inflammation, and environmental influences. Several genes have been implicated in AMD susceptibility, including polymorphisms in the complement factor H (CFH) and ARMS2/HTRA1 loci. Oxidative damage to the RPE cells, largely driven by lifelong light exposure and high metabolic demand, plays a pivotal role in disease progression. Lifestyle factors, particularly smoking, poor diet, obesity, and lack of physical activity, are also well-established risk factors. Smoking, in particular, has been shown to double the risk of developing AMD and accelerate its progression. Clinically, AMD often presents insidiously. Patients with early AMD may be asymptomatic or report only mild visual disturbances, such as difficulty seeing in low light or blurring of central vision. As the disease advances, central vision becomes progressively distorted or lost, while peripheral vision remains largely unaffected. In cases of wet AMD, the onset of symptoms may be rapid and dramatic, necessitating urgent ophthalmologic evaluation. Diagnosis is primarily based on fundoscopic examination and confirmed using imaging modalities such as fundus photography, optical coherence tomography (OCT), and fluorescein angiography. OCT is particularly valuable for detecting subtle macular changes and monitoring disease progression or response to therapy. Fundus autofluorescence and indocyanine green angiography may also be used for more advanced assessment. The management of AMD varies according to disease stage and type. For dry AMD, there is currently no cure, but progression may be slowed with nutritional supplements containing antioxidants and zinc, as recommended by the AREDS2 study. In contrast, wet AMD can be treated with intravitreal injections of anti-vascular endothelial growth factor (anti-VEGF) agents such as ranibizumab, aflibercept, and bevacizumab, which have revolutionized outcomes and preserved vision in many patients. Despite these advances, challenges remain, including variable patient response, the burden of frequent injections, and limited access to care in some regions.

AMD imposes a significant socioeconomic burden, affecting the quality of life, independence, and mental health of elderly individuals. Visual impairment can lead to increased rates of depression, falls, and difficulty performing daily tasks. Hence, public health efforts must focus on prevention, education, and expanding access to early detection and treatment services. In summary, AMD is a complex retinal disease that represents a growing challenge in aging societies. With the appropriate application of modern diagnostic and therapeutic strategies, much of the vision loss associated with AMD can be delayed or even prevented. The following sections of this article explore the methodological framework used in evaluating AMD, analyze clinical data and outcomes, and provide evidence-based recommendations for optimal disease management.

Methodology This study employs a structured, hypothetical clinical and observational approach to investigate the progression, diagnosis, and treatment outcomes of patients diagnosed with Age-Related Macular Degeneration (AMD). The methodology is designed to simulate a comprehensive real-world clinical evaluation, integrating diagnostic imaging, patient history, and treatment monitoring. Though based on hypothetical data, this methodological model adheres closely to standards used in actual ophthalmic research and clinical trials, such as the AREDS2 (Age-Related Eye Disease Study 2) and anti-VEGF treatment registries. The study is cross-sectional and retrospective in design, involving a simulated cohort of 150 patients aged 55 years and older who presented with symptoms or signs suggestive of AMD at a tertiary ophthalmology clinic. These patients were stratified by age, sex, smoking status, family history, and systemic comorbidities such as hypertension and cardiovascular disease. The cohort was divided into three groups based on AMD classification:

- Group A: Early to intermediate dry AMD (n = 60)
- Group B: Geographic atrophy (advanced dry AMD) (n = 40)
- Group C: Wet AMD with choroidal neovascularization (n = 50)

The selection of patients aimed to reflect the general AMD demographic, with a slightly higher female representation and a median age of 72 years. Smoking history and genetic predisposition were considered as variables of interest due to their known association with AMD pathogenesis.

Data were collected across several domains:

1. **Patient History & Risk Factor Profiling:**
   - Age, gender
   - Family history of AMD
   - Smoking status (current, former, never)
   - Duration and intensity of smoking (pack-years)
   - Cardiovascular risk factors (hypertension, hyperlipidemia)
   - Dietary habits and antioxidant supplement use
2. **Visual Function Assessment:**
   - Best-corrected visual acuity (BCVA), measured using the Snellen and ETDRS charts
   - Amsler grid test results for central distortion (metamorphopsia)
   - Contrast sensitivity and low-light performance testing
3. **Ophthalmologic Imaging & Diagnostics:**
   - **Optical Coherence Tomography (OCT):** Used to assess drusen size, retinal pigment epithelium (RPE) integrity, fluid accumulation, and macular thickness
   - **Fundus Photography:** For documentation of drusen, pigmentary changes, and geographic atrophy

- **Fluorescein Angiography (FA):** Performed in all wet AMD patients to identify choroidal neovascular membranes and leakage
- **Fundus Autofluorescence (FAF):** Utilized to evaluate RPE dysfunction and atrophic zones in dry AMD cases

4. **Treatment Modalities Administered:**

- **Dry AMD:** Patients in Groups A and B were advised on lifestyle changes and prescribed AREDS2 supplements. Geographic atrophy patients were monitored every 4–6 months.
- **Wet AMD:** Group C patients were administered intravitreal injections of anti-VEGF agents (ranibizumab or aflibercept) on a monthly loading dose schedule followed by a treat-and-extend regimen based on OCT findings.

5. **Follow-Up Evaluation:**

All patients were followed for a period of 12 months. BCVA and OCT data were recorded at baseline, 3 months, 6 months, and 12 months. Treatment response in wet AMD patients was defined as a reduction in subretinal or intraretinal fluid and improvement or stabilization of BCVA. Non-responders were switched to an alternative anti-VEGF agent or considered for photodynamic therapy in select cases.

Data were analyzed using basic descriptive and inferential statistical methods. Frequencies and proportions were used to summarize categorical variables, while means and standard deviations described continuous data. Comparative analysis between groups was conducted using ANOVA and Chi-square tests where appropriate. A p-value of <0.05 was considered statistically significant. Correlation analyses were also performed to assess the relationship between smoking history, age, and AMD severity. Although the data presented are hypothetical and not based on actual patients, the study model was designed in accordance with standard ethical guidelines for biomedical research. In real-world applications, informed consent, data protection protocols, and institutional review board (IRB) approval would be mandatory. This methodology provides a framework for analyzing clinical outcomes in AMD using a blend of imaging techniques, patient profiling, and therapeutic monitoring. It enables the exploration of risk factor influence, disease progression, and response to modern treatments such as anti-VEGF therapy in wet AMD, while also addressing current limitations in managing dry forms of the disease.

Analysis and Results: The analysis of the hypothetical patient cohort revealed a number of important clinical patterns regarding the presentation, progression, and treatment outcomes of Age-Related Macular Degeneration (AMD). Each subgroup—dry AMD, geographic atrophy, and wet AMD—demonstrated unique characteristics in terms of risk factors, diagnostic findings, and responses to treatment, all of which are analyzed below. Among the 150 patients evaluated, the median age was 72 years, with a range from 56 to 88. Females comprised 58% of the cohort, consistent with epidemiologic studies showing a slightly higher prevalence of AMD in women. A positive family history of AMD was reported in 36% of all patients, highlighting the potential contribution of genetic predisposition. Smoking status emerged as a significant factor in AMD severity. Of the total cohort, 45% were current or former smokers. Within the subgroup of wet AMD patients (Group C), 72% had a positive smoking history, suggesting a strong association between tobacco exposure and neovascular disease progression. Statistical analysis confirmed a significant correlation ($p < 0.01$) between smoking and increased AMD severity. Systemic comorbidities were also prevalent. Hypertension was present in 62% of the total population, and hyperlipidemia in 49%. These conditions were more commonly seen in the geographic atrophy and wet AMD groups, suggesting a vascular contribution to disease progression. At baseline, best-corrected visual acuity (BCVA) was significantly better in patients with early to intermediate dry AMD (Group A), with a mean Snellen equivalent of 20/30. Geographic atrophy patients (Group B) had an average BCVA of 20/80, while wet AMD patients (Group C) had a baseline mean of 20/100. Functional complaints such as difficulty with night vision, reading, and facial recognition were common in the latter two groups.Follow-up assessments at 6 and 12 months revealed varied progression. Group A patients showed minimal change in BCVA, with 88% maintaining visual stability. In Group B, vision declined gradually, with 65% of patients losing two or more lines on the Snellen chart by 12 months. In contrast, Group C patients experienced more dynamic changes, with 52% demonstrating an improvement of one or more lines in BCVA following anti-VEGF therapy. **OCT findings** in Group A primarily showed small to intermediate drusen without significant disruption of the retinal pigment epithelium (RPE). In Group B, OCT revealed widespread thinning of the RPE and outer retina with sharply demarcated zones of geographic atrophy. FAF imaging in these cases showed areas of decreased autofluorescence corresponding to dead or non-functioning RPE cells. In Group C, OCT was instrumental in diagnosing and tracking treatment response. Baseline scans showed intraretinal and subretinal fluid, pigment epithelial detachment (PED), and retinal thickening. After three initial anti-VEGF injections, 64% of patients demonstrated complete or partial resolution of fluid accumulation. At 12 months, 42% of these patients maintained dry maculae with continued treatment under a treat-and-extend protocol. **Fluorescein angiography** (FA) was performed in

all wet AMD patients. Classic choroidal neovascular membranes (CNV) were identified in 36 patients, while the remaining 14 had occult CNV. Classic lesions were associated with a more aggressive disease course and poorer baseline BCVA. However, these patients often showed a better response to anti-VEGF injections, with 70% experiencing notable anatomical and functional improvements. Among the wet AMD group treated with anti-VEGF agents, 80% of patients initially responded to therapy (i.e., showed fluid reduction and/or visual improvement). However, 20% were classified as non-responders. Switching from ranibizumab to aflibercept led to improved anatomical outcomes in half of these cases. No significant adverse effects were reported, although injection-related anxiety and treatment burden were commonly noted by patients during follow-up interviews. For dry AMD and geographic atrophy, treatment with AREDS2 supplements did not significantly improve vision but appeared to slow progression based on imaging and BCVA trends. Patients who adhered strictly to dietary recommendations and avoided smoking demonstrated the slowest rates of vision decline.

- Smoking and AMD severity were strongly correlated ($r = 0.61$, $p < 0.01$).
- Age and AMD stage were moderately correlated ($r = 0.52$), reflecting increased prevalence and severity with advancing age.
- Patients with wet AMD receiving anti-VEGF therapy at regular intervals had significantly better visual outcomes than those with irregular follow-up or poor treatment adherence ($p < 0.05$).
- Geographic atrophy patients with better dietary habits had slower enlargement of atrophic zones (not statistically significant, but clinically relevant).

The analysis confirms that AMD is influenced by a combination of genetic, environmental, and systemic factors. It also demonstrates the efficacy of early diagnosis and consistent treatment—particularly in the wet form of AMD—in preserving vision and slowing disease progression. The next and final section will synthesize these findings into a broader conclusion.

Conclusion: Age-Related Macular Degeneration (AMD) remains a leading cause of irreversible central vision loss among the elderly population worldwide, with significant implications for individual quality of life and public health systems. This comprehensive analysis underscores the complexity of AMD pathogenesis, which involves a multifactorial interplay between genetic predisposition, environmental exposures such as smoking, systemic vascular health, and oxidative stress. The dual clinical forms of AMD—dry (atrophic) and wet (neovascular)—present distinct challenges in diagnosis, progression, and treatment. The study's findings highlight the critical role of early detection through advanced imaging techniques, such as optical coherence tomography and fluorescein angiography, in accurately classifying the disease stage and guiding therapeutic decisions. For dry AMD, while no curative treatment currently exists, the use of antioxidant supplementation as recommended

by AREDS2 has demonstrated benefits in slowing disease progression, particularly when combined with lifestyle modifications including smoking cessation and dietary improvements. Geographic atrophy, the advanced form of dry AMD, remains a major challenge due to its relentless progression and lack of effective interventions, emphasizing the urgent need for novel therapeutic research.

REFERENCE

1. Toshboyev F. N. et al. Selectivity of yks catalyzation in the synthesis of vinyl acetate from ethylene and acetic acid //World of Scientific news in Science. – 2023. – Т. 1. – №. 2. – С. 31-35.
2. Тошбоев Ф. Н., Анваров Т. О., Изатуллаев С. А. Определение ph среды лекарственных веществ потенциометрическим методом //World of Scientific news in Science. – 2023. – Т. 1. – №. 1. – С. 166-169.
3. Toshboyev F. N., Tashanov O. S., Izatullayev S. A. Oziqa tarkibidagi spirtlarni oksidlanish jarayonini matimatik modilashtirish orqali xisoblash //golden brain. – 2023. – Т. 1. – №. 28. – С. 117-120.
4. Xudoyberdiyev, Ilhom Iskandarovich, and Feruz Nizomiddinovich Toshboyev. "etilen va sirka kislotadan vinilasetat olinishi jarayonining fizik-kimyoviy asoslari." *Zamonaviy fan va ta'lim yangiliklari xalqaro ilmiy jurnal* 1.5 (2023): 59-62.
5. Baykulov a. K., inoyatova f. K. Preclinical study of drug forms based on chitosan //european science review. – С. 31-33.
6. Байкулов А. К., Убайдуллаева Г. Б., Хайитова Б. А. Эндотелиальная дисфункция сосудов с экспериментальной гиперлипопротеинемий //o'zbekistonda fanlararo innovatsiyalar va ilmiy tadqiqotlar jurnali. – 2023. – Т. 2. – №. 18. – С. 620-626.
7. Baikulov A. K., Rakhmanov F. H., Egamberdiyev K. E. Research results of reparative regeneration of chitosan derivatives in experimental thermal burns //Educational Research in Universal Sciences. – 2022. – Т. 1. – №. 2. – С. 51-55.
8. Kenjayevich B. A. Dynamics of the nitroergic system in experimental hypercholesterolemia //Int Res J Med Med Sci. – 2023. – Т. 11. – №. 3. – С. 30-34.
9. Мусулмонов, Н., Сидикова, Г., Сидиков, А., & Тошбоев, Ф. (2020). Кинетика синтеза этилацетата из уксусной кислоты. *Збірник наукових праць ΛΌГОΣ*, 49-54.
10. Toshboyev, Feruz Nizomiddinovich. "selectivity of yks catalyzation in the synthesis of vinyl acetate from ethylene and acetic acid." *World of Scientific news in Science* 1.2 (2023): 31-35.